Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4 Thoracic 2 Other hematologic neoplasm 2 Tumor-Agnostic 1 Myeloid 1 Gynecologic 1 Gastrointestinal 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 153 Carboplatin 123 Bevacizumab 87 Cisplatin 66 pembrolizumab 58 Taxes 51 Gemcitabine 51 liposomal doxorubicin 39 Topotecan 37 olaparib 31 Immunoglobulin G 27 Disulfides 26 Cyclophosphamide 24 Brachytherapy 22 Docetaxel 21 human papillomavirus vaccine, L1 type 16, 18 20 niraparib 19 Platinum 19 Nivolumab 18 Magnetic Resonance Spectroscopy 18 1,2-diaminocyclohexaneplatinum II citrate 18 rucaparib 17 durvalumab 16 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16 Doxorubicin 16 Radiotherapy, Intensity-Modulated 14 Radiation 13 Albumin-Bound Paclitaxel 13 fludarabine phosphate 12 fludarabine 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Tyrosine Kinase Inhibitors × Gynecologic × Clear all

NCT03314740 2025-01-10

BAROCCO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

123 enrolled 14 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡